DOI: 10.1055/s-00000003

Aktuelle Ernährungsmedizin

References

Prado CM, Bekaii-Saab T, Doyle LA et al.
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.

Br J Cancer 2012;
106: 1583-1586

Download Bibliographical Data

Search in:
Access: